Straumann (OTCMKTS:SAUHY) Shares Down 3.6% – Time to Sell?

Shares of Straumann Holding AG (OTCMKTS:SAUHYGet Free Report) traded down 3.6% during mid-day trading on Friday . The company traded as low as $11.52 and last traded at $11.52. Approximately 15,830 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 133,481 shares. The stock had previously closed at $11.95.

Analyst Upgrades and Downgrades

Several analysts have weighed in on SAUHY shares. Morgan Stanley reiterated an “underweight” rating on shares of Straumann in a research note on Tuesday, June 30th. BMO Capital Markets started coverage on shares of Straumann in a report on Wednesday, July 8th. They issued an “outperform” rating on the stock. Citigroup restated a “sell” rating on shares of Straumann in a research note on Thursday, July 9th. Barclays reaffirmed an “overweight” rating on shares of Straumann in a report on Thursday, June 18th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Straumann from a “buy” rating to a “hold” rating in a research note on Friday. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Straumann has an average rating of “Hold”.

Get Our Latest Stock Report on Straumann

Straumann Trading Down 3.3%

The firm has a 50-day moving average of $12.59 and a two-hundred day moving average of $11.71.

About Straumann

(Get Free Report)

Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.

In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.

See Also

Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.